Programmed Death Ligand-1 (PD-L1) Expression in Cervical Squamous Cell Carcinoma: Does it Correlate With Outcomes?

被引:1
|
作者
Monsrud, Ashley L. [1 ]
Avadhani, Vaidehi [1 ]
Mosunjac, Marina B. [1 ]
Flowers, Lisa [2 ]
Krishnamurti, Uma [1 ,3 ]
机构
[1] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA USA
[2] Emory Univ, Dept Gynecol & Obstet, Atlanta, GA USA
[3] Yale Univ, Yale New Haven Hosp, Dept Pathol, Sch Med, 20 York St,Suite EP 732B, New Haven, CT 06510 USA
关键词
Programmed death ligand-1; Cervical cancer; Squamous cell carcinoma; TUMOR-INFILTRATING LYMPHOCYTES; INTRAEPITHELIAL NEOPLASIA; ENHANCED EXPRESSION; CANCER; MORTALITY; PATTERNS; TILS;
D O I
10.1097/PGP.0000000000000975
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Cervical cancer is one of the most common gynecological malignancies. Upregulation of programmed death ligand-1 (PD-L1), an immunoregulatory protein, is associated with an adverse outcomes in several malignancies. Most studies evaluating PD-L1 expression in cervical squamous cell carcinoma (CSCC) lack data on outcomes. In this study, we correlate PD-L1 expression with clinicopathologic factors and clinical outcomes in invasive CSCC. Seventy-three cases of CSCC from 2010 to 2018 were immunostained for PD-L1. A combined positive score (CPS) of >= 1 and >= 10 was correlated with age, stage, and survival outcomes. Kaplan-Meier curves for progression-free survival and overall survival were plotted and compared using the log-rank test. Cox regression analysis was performed to identify significant prognostic factors (2-tailed P<0.05 was considered statistically significant). With CPS >= 1 or >= 10 as the cut-off, PD-L1 was positive in 52/73 (71.2%) and 23/73 (31.5%) of cases, respectively. PD-L1 positive patients present at a higher stage of disease, especially those with CPS >= 10. With CPS of >= 10 as the cut-off, the 5-yr progression-free survival and 5-yr overall survival were significantly lower (P = 0.034 and 0.012, respectively). Only stage was statistically significant for worse overall survival on multivariate analysis. PD-L1 positive patients present at a higher stage of disease, and stage is an independent prognostic indicator for adverse outcomes in CSCC. This study highlights the potential of PD-L1 targeted therapy in patients with CSCC.
引用
收藏
页码:535 / 543
页数:9
相关论文
共 50 条
  • [31] Expression of programmed death ligand-1 (PD-L1) and tumor infiltrating lymphocytes (TILs) in breast carcinoma and their clinical significance
    Mondal, Santosh Kumar
    Bhattacharya, Saptarshi
    Sarkar, Aditya Prasad
    Saha, Rama
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) : S81 - S86
  • [32] Does Programmed Cell Death 1 Ligand (Pd-L1) Expression Predict Recurrence in Women With Endometrioma?
    Celik, Hale Goksever
    Celik, Engin
    Uhri, Mehmet
    Bastu, Ercan
    Gungor, Mete
    Buyru, Faruk
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [33] In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
    Reddy, Vishwanatha R. A. P.
    Mwangi, William
    Sadigh, Yashar
    Nair, Venugopal
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2019, 9
  • [34] Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells
    Shwe, Thuzar Hla
    Pothacharoen, Peraphan
    Phitak, Thanyaluck
    Wudtiwai, Benjawan
    Kongtawelert, Prachya
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [35] Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis
    Xu, Feng
    Xu, Lingling
    Wang, Qian
    An, Guangyu
    Feng, Guosheng
    Liu, Fuquan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (09): : 14595 - 14603
  • [36] Programmed death-ligand 1 (PD-L1) expression in small cell carcinoma of bladder.
    Sanguino, Angela
    Samiei, Arash
    Pasricha, Gurleen
    Harinath, Lakshmi
    Miller, Ralph
    Lyne, John
    Silverman, Jan F.
    Mao, Shifeng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma
    Hanna, Glenn J.
    Kacew, Alec J.
    Tanguturi, Anusha R.
    Grote, Hans J.
    Vergara, Victoria
    Brunkhorst, Beatrice
    Rabinowits, Guilherme
    Thakuria, Manisha
    LeBoeuf, Nicole R.
    Ihling, Christian
    DeCaprio, James A.
    Lorch, Jochen H.
    FRONTIERS IN MEDICINE, 2020, 7
  • [38] Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma
    Richter, Igor
    Jirasek, Tomas
    Cermakova, Eva
    Bartos, Jiri
    Buchler, Tomas
    Dvorak, Josef
    JOURNAL OF BUON, 2019, 24 (05): : 2155 - 2160
  • [39] Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung
    Imanishi, Naoko
    Hirai, Ayako
    Yoneda, Kazue
    Shimajiri, Shohei
    Kuwata, Taiji
    Tashima, Yuko
    Takeuchi, Masahiro
    Iwai, Yoshiko
    Ichiki, Yoshinobu
    Tanaka, Fumihiro
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (07) : 1563 - 1569
  • [40] Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma
    de Souza Malaspina, Tatiana Salles
    Gasparoto, Thais Helena
    Sales Nogueira Costa, Maria Renata
    de Melo, Edgard Franco, Jr.
    Valerio Ikoma, Maura Rosane
    Damante, Jose Humberto
    Cavassani, Karen Angelica
    Garlet, Gustavo Pompermaier
    da Silva, Joao Santana
    Campanelli, Ana Paula
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (07) : 965 - 974